

CASE STUDY

Empowering Client Success: Unveiling the Disease Landscape of Hyperphosphatemia

Client's Challenge and Goal

Our client was working in the area of Hyperphosphatemia. Clinical trial data analysis was essential for the client to make informed decisions during their drug discovery journey.

The client was working on collecting and analyzing the vast amount of clinical trial data associated with hyperphosphatemia. The task of gathering comprehensive information on drug doses, efficacy, and endpoints required extensive expertise and resources that the client lacked in-house. Realizing the complexity and time-consuming nature of this endeavor, they turned to Excelra for support. Excelra's specialized capabilities in data collection, analysis, and disease landscape curation made them the ideal partner to tackle this challenge. By leveraging Excelra's expertise the client gained access to the valuable clinical trial data that they needed to make well-informed decisions, ultimately advancing their research program on hyperphosphatemia.



Concepts explored for hyperphosphatemia disease landscape

Our Client


A well established Biotech firm based out of US.

Our Approach


Through meticulous data mining, Excelra's team collected the necessary information from various repositories such as CT.gov, JMACTR, UMIN-CTR, and others. They carefully shortlisted clinical trials that aligned with the client's criteria.

Next, Excelra's subject matter experts curated the selected trials, extracting essential data on efficacy, dose, and endpoints. This data underwent thorough analysis and preparation to ensure its accuracy and relevance.

Excelra delivered the data to the client, meeting the required standards. This comprehensive package provided the client with valuable insights to support their ongoing research program on hyperphosphatemia.



Excelra also prepared a comprehensive landscape of phosphate binders. The pill burden and adverse effects (particularly gastrointestinal intolerance) associated with phosphate binders often contribute to poor medication adherence.



Our Solution

As a result of Excelra's meticulous data mining and curation, the client received a comprehensive dataset comprising of clinical studies focused on hyperphosphatemia and phosphate binders. This dataset delivered clear insights into the relationships between dose efficacy and endpoints, shedding light on the optimal dosing strategies for addressing hyperphosphatemia.

At the end of Excelra's investigation into phosphate binders, data relating to indications, reported efficacy, dosages, and physicochemical properties were revealed. These valuable findings gave the client a deeper understanding of the dose efficacy and endpoint relationships, the client enabled them to make informed decisions regarding treatment strategies for hyperphosphatemia. This knowledge enhanced their ability to design effective clinical trials, optimize dosage regimens, and potentially accelerate the development of novel therapeutics in the fight against this condition.

Conclusion

Excelra's comprehensive and insightful dataset empowered the client to make data-driven decisions and advance their research in hyperphosphatemia. By harnessing these results, the client further contributed to the scientific community's understanding of the disease and improved patient outcomes for the future.

Where data means more

excelra

SAN FRANCISCO • BOSTON • LONDON • GHENT/GENT
SCHIPHOL • UTRECHT • BASEL • BIELEFELD • HYDERABAD

Connect with our experts: marketing@excelra.com

www.excelra.com